First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.

被引：0
|
作者：
Camidge, D. Ross
Bazhenova, Lyudmila
Salgia, Ravi
Weiss, Glen J.
Langer, Corey J.
Shaw, Alice Tsang
Narasimhan, Narayana I.
Dorer, David J.
Rivera, Victor M.
Zhang, Joshua
Clackson, Tim
Haluska, Frank G.
Gettinger, Scott N.
机构：
[1] Univ Colorado, Ctr Canc, Aurora, CO USA
[2] UC San Diego Moores Canc Ctr, La Jolla, CA USA
[3] Univ Chicago, Chicago, IL 60637 USA
[4] Virginia G Piper Canc Ctr, Scottsdale Healthcare Program, Scottsdale, AZ USA
[5] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[6] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[7] ARIAD Pharmaceut Inc, Cambridge, MA USA
[8] Yale Univ, Sch Med, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8031
引用
收藏
页数：1
相关论文
共 50 条
  • [21] CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
    Sanborn, Rachel E.
    Hamid, Omid
    de Vries, Elisabeth Ge
    Ott, Patrick A.
    Garcia-Corbacho, Javier
    Boni, Valentina
    Bendell, Johanna
    Autio, Karen A.
    Cho, Daniel C.
    Plummer, Ruth
    Stroh, Mark
    Lu, Lawrence
    Thistlethwaite, Fiona
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
  • [22] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Infante, Jeffrey R.
    Mendelson, David S.
    Burris, Howard A., III
    Bendell, Johanna C.
    Tolcher, Anthony W.
    Gordon, Michael S.
    Gillenwater, Heidi H.
    Arastu-Kapur, Shirin
    Wong, Hansen L.
    Papadopoulos, Kyriakos P.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 216 - 224
  • [23] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Jeffrey R. Infante
    David S. Mendelson
    Howard A. Burris
    Johanna C. Bendell
    Anthony W. Tolcher
    Michael S. Gordon
    Heidi H. Gillenwater
    Shirin Arastu-Kapur
    Hansen L. Wong
    Kyriakos P. Papadopoulos
    Investigational New Drugs, 2016, 34 : 216 - 224
  • [24] Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors
    Iwasa, Satoru
    Yamamoto, Noboru
    Shitara, Kohei
    Tamura, Kenji
    Matsubara, Nobuaki
    Tajimi, Masaomi
    Lin, Aimee B.
    Asou, Hiroya
    Cai, Zhihong
    Inoue, Koichi
    Shibasaki, Yuko
    Saito, Kanako
    Takai, Hiroki
    Doi, Toshihiko
    CANCER SCIENCE, 2018, 109 (10): : 3216 - 3223
  • [25] A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results.
    Capelan, Marta
    Kumar, Prasana
    Tolcher, Anthony W.
    Zivi, Andrea
    Desai, Madhuri
    Papadopoulos, Kyriakos P.
    Senaldi, Giorgio
    Patnaik, Amita
    Banerji, Udai
    Rasco, Drew D.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [26] First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.
    Mehra, Ranee
    Camidge, D. Ross
    Sharma, Sunil
    Felip, Enriqueta
    Tan, Daniel Shao-Weng
    Vansteenkiste, Johan F.
    De Pas, Tommaso Martino
    Kim, Dong-Wan
    Santoro, Armando
    Liu, Geoffrey
    Goldwasser, Meredith
    Dai, David
    Radona, Marietta
    Boral, Anthony
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] First-in-human study of the cancer peptide vaccine, TAS0313, in patients with advanced solid tumors: phase I dose finding part results
    Yamamoto, Noboru
    Sato, Jun
    Iwasa, Satoru
    Yonemori, Kan
    Koyama, Takafumi
    Tamura, Kenji
    Shimizu, Toshio
    Kondo, Syunsuke
    Kitano, Shigehisa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [28] Phase I dose-finding study of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (pts) with advanced malignancies
    Bechter, O.
    Aftimos, P.
    Awada, A.
    Rottey, S.
    Machiels, J. P.
    Dumez, H.
    Jungels, C.
    Costermans, J.
    Huyvaert, N.
    Zografos, E.
    Meeus, M. A.
    Musa, H.
    Burkard, U.
    Zhao, Y.
    Schoffski, P.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E16 - E16
  • [29] Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
    Pagani, O
    Sessa, C
    Martinelli, G
    Crivellari, D
    Buonadonna, A
    Thürlimann, B
    Hess, D
    Borner, M
    Bauer, J
    Zampino, G
    Zimatore, M
    Graffeo, R
    Riva, A
    Goldhirsch, A
    ANNALS OF ONCOLOGY, 1999, 10 (05) : 539 - 545
  • [30] A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies
    Ossenkoppele, Gert J.
    Lowenberg, Bob
    Zachee, Pierre
    Vey, Norbert
    Breems, Dimitri
    Van de Loosdrecht, Arjan A.
    Davidson, Alan H.
    Wells, Graham
    Needham, Lindsey
    Bawden, Lindsay
    Toal, Martin
    Hooftman, Leon
    Debnam, Phillip M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (02) : 191 - 201
12345